Health
As Trump Targets Researchers, Europe Makes a Pitch to Attract Scientists
As the Trump administration slashes support to research institutions and threatens to freeze federal funding to universities like Harvard and Columbia, European leaders are offering financial help to U.S.-based researchers and hoping to benefit from what they are calling a “gigantic miscalculation.”
“Nobody could imagine a few years ago that one of the great democracies of the world would eliminate research programs on the pretext that the word ‘diversity’ appeared in its program,” President Emmanuel Macron of France said on Monday.
He was speaking at the Sorbonne University in Paris during an event called Choose Europe for Science that was organized by the French government and the European Union.
It was unthinkable, Mr. Macron said, alluding also to the withdrawal of researchers’ visas in the United States, that a nation whose “economy depends so heavily on free science” would “commit such an error.”
Ursula von der Leyen, president of the European Commission, announced an investment of 500 million euros, or $566 million, at the conference to “make Europe a magnet for researchers” over the next two years.
Although that amount is not much compared to the billions in cuts American universities face, it comes on top of the $105 billion international research program called Horizon Europe that supports scientific breakthroughs, like genome sequencing and mRNA vaccines, Ms. Von der Leyen said.
She did not mention the United States by name, but she described a global environment where “fundamental, free and open research is questioned.”
“What a gigantic miscalculation!” she said.
In Europe, there is a widespread feeling that Mr. Trump has abandoned America’s traditional support for liberty, free speech and democracy through his embrace of autocrats and the assault on science and academia. That has created strains but also a sense of opportunity on the continent, where attracting the best scientific minds to vigorous and independent universities is seen as part of a broader campaign to “rearm” Europe as an independent power.
Over the longer term, the European Commission, the executive arm of the European Union, plans to double grants for researchers who relocate and to enshrine freedom of scientific research into a law called the European Research Area Act.
“The first priority is to ensure that science in Europe remains open and free. That is our calling card,” Ms. von der Leyen said.
The Trump administration’s attack on science and threats to universities were the main impetus for the conference, which was attended by government ministers and prominent researchers from across Europe. Increasingly, the United States is seen as a strategic adversary, and opening doors to American researchers and scientists is viewed as a long-term response to that challenge.
Mr. Macron’s message to scientists was this: “If you love freedom, come help us to remain free.”
France announced its own program to lure U.S.-based researchers last month. The government promised universities and research institutions in the country up to 50 percent of the funding needed to lure international researchers, including those working in areas under pressure from the Trump administration like climate studies and low carbon energy. But no particular funding was announced until Monday, when Mr. Macron said his government would commit $113 million to the program.
Alarms in Europe began sounding when the Trump administration slashed jobs and froze science grants at leading American institutions as part of cost-cutting measures. European dismay increased when the U.S. government attacked diversity programs and attempted to dictate to universities “whom they can admit and hire, and which areas of study and inquiry they can pursue,” in the words of Harvard’s president, Alan M. Garber.
Harvard has filed a lawsuit against the Trump administration over its $2.2 billion federal funding freeze. Mr. Trump mused last week about ending Harvard’s tax-exempt status.
The U.S. government has also fired staff at U.S. centers deemed to be at the pinnacle of scientific research, including at the National Oceanic and Atmospheric Administration, the National Science Foundation, the Centers for Disease Control and Prevention and the National Institutes of Health, the world’s largest funder of biomedical research.
At the same time, some federal agencies have removed words from websites and grant applications that were deemed unacceptable to the Trump administration. Among the terms considered taboo are “climate science,” “diversity” and “gender.”
Taken together, the actions have sent a chill through academia and research institutes, with scientists worried not just for their jobs but the long-term viability of their research.
“In the United States, once a paradise for researchers, academic freedom is being challenged. The line between truth and falsehood, between fact and belief, is being weakened,” Elisabeth Borne, France’s education minister, said Monday as she opened the conference.
Universities in France have been at the forefront of attempts to benefit from a potential American brain drain. Aix Marseille University is interviewing some 300 candidates for its Safe Place for Science program, which it launched in March in response to the Trump administration’s cuts. Since then, many other universities and institutions have followed suit.
“Our self-interest, as well as our values, now command us to be the refuge for knowledge wherever it is under pressure,” said Luis Vassy, the president of Sciences Po University in Paris.
François Hollande, a former French president, has proposed a law to create a “scientific refugee” status for researchers threatened for their work in their countries.
However, some university heads and professors have criticized the initiative. They argue that while France is attempting to draw American researchers, it has also been cutting higher education and research budgets to address the country’s ballooning budget deficit.
NEWYou can now listen to Fox News articles!
Those at risk of type 2 diabetes may be able to prevent heart problems later.
A new study published in The Lancet Diabetes & Endocrinology discovered that lowering the blood sugar of those with prediabetes could reduce the risk of heart attack by half.
Diabetes researchers and endocrine experts across Europe, China and the U.S. investigated how bringing blood sugar back to normal levels affected the chances of heart problems later in life, based on a 20-year American study and a 30-year Chinese study, according to a press release.
CLICK HERE FOR MORE HEALTH STORIES
In both studies, the prediabetic participants were coached to make appropriate lifestyle changes to lower blood sugar (the amount of glucose in the bloodstream) through diet and exercise, also targeting weight loss.
Participants worked to lower blood sugar through diet and exercise targeted at weight loss. (iStock)
The researchers split the participants into a remission group (where blood sugar returned to normal) and a non-remission group, which included those still in the prediabetes range. They then determined who in these groups had died from heart disease or were hospitalized for heart failure.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Participants who went into remission had a 58% lower risk of dying from heart disease and being hospitalized for heart failure. This group also had a lower risk of other major heart events and lower overall death rates.
These heart-protective benefits lasted for decades after the program ended, the researchers found.
Those in prediabetes remission had their risk of a heart event reduced by more than half. (iStock)
“Reaching prediabetes remission is linked to a decades-long benefit, halving the risk of cardiovascular death or hospitalization for heart failure in diverse populations,” the researchers commented in the publication of the study. “Targeting remission might represent a new approach to cardiovascular prevention.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
In an interview with Fox News Digital, Dr. Andreas Birkenfeld, study co-author and professor of medicine at the University Hospital Tübingen in Germany, reiterated that reaching prediabetes remission is not only relevant for reducing the progression of type 2 diabetes, but may also be associated with a “meaningful reduction in… heart attack risk, cardiac death and heart failure.”
“Importantly, this underscores that prediabetes is a modifiable stage where timely, evidence-based interventions (especially lifestyle measures, and in selected cases, medication) can make a real difference,” he added.
“Reaching prediabetes remission is linked to a decades-long benefit, halving the risk of cardiovascular death or hospitalization for heart failure in diverse populations,” the researchers commented. (iStock)
The study did have some limitations, including that it is based on analysis of trials not originally designed to measure cardiovascular outcomes, which means the results show association but cannot prove causation.
In addition, unmeasured lifestyle and health factors, population differences and lack of randomization for heart outcomes may have influenced the reduced cardiovascular risk, the researchers acknowledged.
“This underscores that prediabetes is a modifiable stage where timely, evidence-based interventions … can make a real difference.”
Birkenfeld suggested that those with prediabetes should ask their doctors the following questions: “What is my current status? What is my personal cardiovascular risk? What is my target blood glucose level?”
Patients should also inquire about the frequency of testing for blood sugar and key risk factors like blood pressure, cholesterol and other related conditions, such as kidney function or sleep apnea, he advised.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“If lifestyle changes aren’t enough or my risk is high, would medication be appropriate for me — and what are the benefits and downsides?” the researcher asked as an example.
About 98 million American adults, more than one in three, have prediabetes, according to CDC data. Eight in 10 of these adults are unaware that they have the disease.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
One of the most widely known risks linked to the COVID-19 vaccine is myocarditis, especially in young males — and now a new Stanford study has shed some light on why this rare effect can occur.
Myocarditis, which is inflammation of the heart, occurs in about one in 140,000 people who receive the first dose of the vaccine and one in 32,000 after the second dose, according to a Stanford press release. Among males 30 and younger, that rises to one in 16,750.
Symptoms of the condition include chest pain, shortness of breath, fever and palpitations, which can occur just one to three days after vaccination. Another marker is heightened levels of cardiac troponin, which indicates that the heart muscle has been damaged.
LOWER DEMENTIA RISK LINKED TO ROUTINE VACCINATION IN MAJOR NEW ANALYSIS
In most cases, people who experience myocarditis recover quickly and restore full heart function, according to study author Joseph Wu, MD, PhD, the director of the Stanford Cardiovascular Institute and a professor of medicine and radiology.
One of the most widely known risks linked to the COVID-19 vaccine is myocarditis, especially in young males. (iStock)
“It’s not a heart attack in the traditional sense,” Wu told Fox News Digital. “There’s no blockage of blood vessels as found in most common heart attacks. When symptoms are mild and the inflammation hasn’t caused structural damage to the heart, we just observe these patients to make sure they recover.”
In rare cases, however, severe heart inflammation can lead to hospitalizations, critical illness or death, Wu noted.
Finding the cause
The new Stanford study — conducted in collaboration with The Ohio State University — aimed to determine the reasons for the myocarditis. The research team analyzed blood samples from vaccinated people, some with myocarditis and some without.
They found that those with myocarditis had two proteins in their blood, CXCL10 and IFN-gamma, which are released by immune cells. Those proteins then activate more inflammation.
COVID VACCINE UNDER NEW SCRUTINY AFTER STUDIES REVEAL POSSIBLE HEALTH RISKS
“We think these two are the major drivers of myocarditis,” said Wu. “Your body needs these cytokines to ward off viruses. It’s essential to immune response, but can become toxic in large amounts.”
In mouse and heart tissue models, high levels of these proteins led to signs of heart irritation, similar to mild myocarditis.
Prevention mechanism
“One of the most striking findings was how much we could reduce heart damage in our models by specifically blocking these two cytokines, without shutting down the entire (desired) immune response to the vaccine,” Wu told Fox News Digital, noting that a targeted, “fine‑tuning” immune approach might be enough to protect the heart.
Myocarditis, which is inflammation of the heart, occurs in about one in 140,000 people who receive the first dose of the vaccine and one in 32,000 after the second dose. (iStock)
“This points to a possible future way to prevent or treat myocarditis in people who are at the highest risk, while keeping the benefits of vaccination,” he added.
The team also found that genistein, an estrogen-like natural compound found in soybeans, reduced inflammation in lab tests, but this has not yet been tested in humans.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The findings were published in the journal Science Translational Medicine.
“This is a very complex study,” Fox News senior medical analyst Dr. Marc Siegel told Fox News Digital. “Myocarditis is very rare, and the immune mechanism makes sense.”
CLICK HERE FOR MORE HEALTH STORIES
“Myocarditis is worse with COVID — much more common, and generally much more severe.”
Wu agreed, adding that COVID infection is about 10 times more likely to cause myocarditis compared to mRNA-based vaccines.
‘Crucial tool’
The researchers emphasized that COVID-19 vaccines have been “heavily scrutinized” for safety and have been shown to have an “excellent safety record.”
In rare cases, however, severe heart inflammation can lead to hospitalizations, critical illness or death. (iStock)
“mRNA vaccines remain a crucial tool against COVID‑19, and this research helps explain a rare side effect and suggests ways to make future vaccines even safer, rather than a reason to avoid vaccination,” Wu said.
“The overall benefits of COVID‑19 vaccination still clearly outweigh the small risk of myocarditis for nearly all groups.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The study did have some limitations, primarily the fact that most of the data came from experimental systems (mice and human cells in the lab), which cannot fully capture how myocarditis develops and resolves in real patients, according to Wu.
“This points to a possible future way to prevent or treat myocarditis in people who are at the highest risk.”
“These findings do not change what people should do right now, because our work is still at the preclinical (mouse and human cells) stage,” he said. “Clinical studies will be needed to confirm whether targeted treatments are safe and effective.”
The researcher also added that myocarditis risk could rise with other types of vaccines.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“Other vaccines can cause myocarditis and inflammatory problems, but the symptoms tend to be more diffuse,” he said in the release. “Plus, mRNA-based COVID-19 vaccines’ risks have received intense public scrutiny and media coverage. If you get chest pains from a COVID vaccine, you go to the hospital to get checked out, and if the serum troponin is positive, then you get diagnosed with myocarditis. If you get achy muscles or joints from a flu vaccine, you just blow it off.”
The study was funded by the National Institutes of Health and the Gootter-Jensen Foundation.
State regulators vote to keep utility profits high, angering customers across California
Trump administration, Congress move to cut off transgender care for children
High school basketball: Boys’ and girls’ scores from Wednesday, Dec. 17
Mercosur signature delayed to January after Meloni asks for more time
Is ISIS making a comeback? : Sources & Methods
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Video: ‘It Didn’t Have to Happen This Way:’ U.Va. Faculty Call for Review of Police Response to Protests
Mercosur signature delayed to January after Meloni asks for more time
Is ISIS making a comeback? : Sources & Methods
Texas Republicans launch ‘Sharia Free America Caucus’ aimed at defending ‘Western civilization’
UK police arrest four people for pro-Palestine ‘Intifada’ calls
BBC Verify Live: Fact-checking Trump’s unusual new White House presidential plaques
-
Iowa4 days agoAddy Brown motivated to step up in Audi Crooks’ absence vs. UNI
-
Washington1 week agoLIVE UPDATES: Mudslide, road closures across Western Washington
-
Iowa5 days agoHow much snow did Iowa get? See Iowa’s latest snowfall totals
-
Maine2 days agoElementary-aged student killed in school bus crash in southern Maine
-
Maryland4 days agoFrigid temperatures to start the week in Maryland
-
Technology1 week agoThe Game Awards are losing their luster
-
South Dakota4 days agoNature: Snow in South Dakota
-
Nebraska1 week agoNebraska lands commitment from DL Jayden Travers adding to early Top 5 recruiting class